We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.82%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.17B
AUM Growth
+$18.3M
Cap. Flow
-$273M
Cap. Flow %
-4.42%
Top 10 Hldgs %
39.22%
Holding
178
New
12
Increased
57
Reduced
71
Closed
15

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$25.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
3
EXAS
Exact Sciences
EXAS
+$16.4M
4
ABT icon
Abbott
ABT
+$15.1M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$13M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$36.6M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$34.7M
3
CRL icon
Charles River Laboratories
CRL
+$33.2M
4
ARGX icon
argenx
ARGX
+$29.8M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.04%
3 Communication Services 0.02%
4 Technology 0.01%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSTL icon
51
Castle Biosciences
CSTL
$722M
$36M 0.58%
1,262,030
+44,929
+4% +$1.14M
VRNA
52
DELISTED
Verona Pharma
VRNA
$35.1M 0.57%
1,220,059
+85,830
+8% +$2.11M
VEEV icon
53
Veeva Systems
VEEV
$31.2B
$34.3M 0.56%
163,512
-5,071
-3% -$1M
GMED icon
54
Globus Medical
GMED
$10.4B
$33.6M 0.54%
469,798
-27,495
-6% -$1.94M
WVE icon
55
Wave Life Sciences
WVE
$1.14B
$33.6M 0.54%
4,094,458
– –
TMO icon
56
Thermo Fisher Scientific
TMO
$196B
$33.2M 0.54%
53,623
+10,997
+26% +$6.51M
AXSM icon
57
Axsome Therapeutics
AXSM
$11.9B
$33M 0.53%
367,181
-149,352
-29% -$13M
MGNX icon
58
MacroGenics
MGNX
$291M
$32.7M 0.53%
9,929,963
-12,350
-0.1% -$48.1K
SAGE
59
DELISTED
Sage Therapeutics
SAGE
$32.2M 0.52%
4,460,693
-4,000
-0.1% -$36.6K
IQV icon
60
IQVIA
IQV
$34B
$30.8M 0.5%
129,827
+37,744
+41% +$8.91M
ANNX icon
61
Annexon
ANNX
$957M
$30.5M 0.49%
5,157,290
– –
DHR icon
62
Danaher
DHR
$143B
$29.4M 0.48%
105,590
+21,670
+26% +$5.73M
CRSP icon
63
CRISPR Therapeutics
CRSP
$4.73B
$28.7M 0.46%
610,000
-7,649
-1% -$388K
REGN icon
64
Regeneron Pharmaceuticals
REGN
$70.6B
$28.1M 0.46%
26,776
-5,521
-17% -$6.14M
GPCR icon
65
Structure Therapeutics
GPCR
$3.44B
$27.6M 0.45%
629,758
+72,437
+13% +$2.8M
TMDX icon
66
Transmedics
TMDX
$2.5B
$26.7M 0.43%
169,844
-31,571
-16% -$4.86M
NEO icon
67
NeoGenomics
NEO
$1.88B
$23.8M 0.39%
1,612,612
+410,516
+34% +$6.42M
MOH icon
68
Molina Healthcare
MOH
$11.7B
$23.3M 0.38%
67,562
-8,831
-12% -$2.91M
BMRN icon
69
BioMarin Pharmaceuticals
BMRN
$11.6B
$23.3M 0.38%
330,976
+278,744
+534% +$23.3M
STE icon
70
Steris
STE
$21.1B
$22.1M 0.36%
91,282
– –
HOLX
71
DELISTED
Hologic
HOLX
$20.2M 0.33%
247,864
+38
+0% +$3.04K
SIBN icon
72
SI-BONE Inc
SIBN
$766M
$20.2M 0.33%
1,444,109
+56,500
+4% +$850K
PRVA icon
73
Privia Health
PRVA
$3.34B
$19.3M 0.31%
1,059,171
– –
MCK icon
74
McKesson
MCK
$97.8B
$17.7M 0.29%
35,742
-10,400
-23% -$5.79M
NTRA icon
75
Natera
NTRA
$38.3B
$17.6M 0.28%
138,459
-75,528
-35% -$8.67M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2024 Portfolio in Review

As of Q3 2024, Bellevue Group held 178 positions worth $6.17B, up 0.3% from $6.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group withdrew a net $273M in Q3 2024, closing 15 positions and reducing 71 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Terns Pharmaceuticals worth $8.69M.

  • Bellevue Group's largest Q3 2024 buy was Terns Pharmaceuticals: 1,042,135 shares worth $8.69M.
  • Bellevue Group added most to Evolent Health in Q3 2024, an estimated $25.8M increase.
  • Bellevue Group's biggest Q3 2024 reduction was Insmed, cutting an estimated $36.6M.
  • Bellevue Group fully exited Silk Road Medical, Inc. Common Stock in Q3 2024, selling an estimated $23.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $6.17B portfolio in Q3 2024.
  • Bellevue Group opened 12 new positions and closed 15 in Q3 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.17B.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.